Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals (ALNY) is a biotechnology company that develops RNA interference (RNAi) therapeutics to silence disease-causing genes. Investors should know it has moved from research-stage to a commercial entity, with multiple approved medicines for rare genetic disorders — including treatments for hereditary ATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria — and a broad pipeline built on its GalNAc delivery platform. The business is growth-oriented: revenues depend on uptake of marketed drugs, pricing and successful launches of late-stage candidates. Key risks include trial outcomes, regulatory decisions, pricing pressures, manufacturing scale-up and competition from other modalities. With a market capitalisation near $62.13 billion, Alnylam may appeal to investors seeking exposure to innovative therapeutics, but it suits those comfortable with biotech volatility. This is general information for educational purposes only and not personalised investment advice; values can fall as well as rise.
Why It's Moving
Alnylam shakes up board with key resignations and new strategic addition amid debt repurchase.
Alnylam Pharmaceuticals announced board changes on December 3, with directors Michael W. Bonney and Carolyn Bertozzi, Ph.D., resigning effective December 2 to support the company's strategic evolution in rare and prevalent diseases.[3][4] The firm also revealed a partial repurchase of its 1.00% Convertible Senior Notes due 2027 on December 11, signaling confidence in its financial position as it advances a robust pipeline.[6][7]
- Two veteran directors stepped down, paving the way for Stuart A. Arbuckle to join as a new non-employee director starting January 5, 2026, with a $75,000 annual salary and $600,000 in stock options to bolster global expansion efforts.[3]
- The leadership refresh aims to fuel Alnylam's push into a top-tier multi-product biotech, enhancing pipeline progress across hypertension and ATTR amyloidosis programs.[4]
- Partial repurchase of convertible notes underscores proactive balance sheet management, freeing up resources for innovation and growth initiatives.[6]
Alnylam shakes up board with key resignations and new strategic addition amid debt repurchase.
Alnylam Pharmaceuticals announced board changes on December 3, with directors Michael W. Bonney and Carolyn Bertozzi, Ph.D., resigning effective December 2 to support the company's strategic evolution in rare and prevalent diseases.[3][4] The firm also revealed a partial repurchase of its 1.00% Convertible Senior Notes due 2027 on December 11, signaling confidence in its financial position as it advances a robust pipeline.[6][7]
- Two veteran directors stepped down, paving the way for Stuart A. Arbuckle to join as a new non-employee director starting January 5, 2026, with a $75,000 annual salary and $600,000 in stock options to bolster global expansion efforts.[3]
- The leadership refresh aims to fuel Alnylam's push into a top-tier multi-product biotech, enhancing pipeline progress across hypertension and ATTR amyloidosis programs.[4]
- Partial repurchase of convertible notes underscores proactive balance sheet management, freeing up resources for innovation and growth initiatives.[6]
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Alnylam’s stock with a target price suggesting potential growth.
Financial Health
Alnylam Pharmaceuticals is generating strong revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ALNY
Pioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
RNAi platform potential
Alnylam’s GalNAc delivery platform enables targeted gene silencing across liver-related diseases, which could drive long-term growth, though clinical and commercial execution matters.
Clinical catalysts ahead
Late-stage trial readouts and new approvals can be material share-price catalysts; remember that trial or regulatory setbacks can also move the stock substantially.
Rare-disease reach
Market opportunity centres on rare, high‑need conditions where few therapies exist, but pricing, access and competition will influence commercial outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
